See feature articles below:
About Broad Street Alerts:
Big opportunities in Small Cap’s
Broad Street Alerts recent profiles and track record, 217% in verifiable potential gains for our members on the last 4 small cap alerts alone!
February 10th, 2016- (NASDAQ: BONT) opened $1.65/share hit a high of $3.00/share within 30 days our member potential gains- 83%
March 7th, 2016-(NYSE-MKT: FSI) opened at .91/share and hit 1.10/share within 5 days for gains of 21% for our members.
March 24th, 2016- (NASDAQ: ICLD) opened at $.77/share it a high of $1.15/share within 2 days for gains of 49% for our members.
April 11th, 2016 – (NASDAQ: FNJN) called at $1.07/share hit $1.76/share in 3 days for 64% gains for our members.
These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.
We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.
***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.
–Report on: Adamis Pharmaceuticals
SAN DIEGO, April 12, 2016 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (ADMP) (“Company” or “Adamis”) announced today that it has successfully completed its previously announced acquisition (the “Acquisition”) of US Compounding, Inc. (“USC”). Upon the closing of this transaction, USC has become a wholly-owned subsidiary of Adamis.
Dr. Dennis J. Carlo, President and CEO of Adamis, stated, “We are pleased to have completed this transformational acquisition that will expand our product portfolio, provide immediate revenues, as well as significantly increase our manufacturing, sales and marketing capabilities. The combination will now position us to better commercialize our pipeline products upon approval and diversify our revenue mix. Our Epinephrine Pre-filled Syringe (“PFS”) has an FDA agency action date (PDUFA date) of June 4, 2016. The potential revenues from the PFS combined with the anticipated cash flows from USC, should put Adamis in a strong financial position.”
Please see Adamis’ Form 8K filed with the Securities and Exchange Commission for additional details on the transaction.
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of allergy and respiratory disease. The Company’s current specialty pharmaceutical product candidates include the Epinephrine Injection PFS syringe product for use in the emergency treatment of anaphylaxis, APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease, and APC-2000 for the treatment of bronchospasms. Adamis’ wholly-owned subsidiary, US Compounding, is a 503B drug outsourcing facility that provides prescription medications to patients, physician clinics, hospitals and surgery centers throughout most of the United States.
Source – ADMP Press Release
Broad street alerts has not been compensated for the mention of any publicly traded companies in this article nor do we own positions in any of the companies in this article.
Broad Street Alerts was previously compensated eighteen thousand five hundred dollars by star media llc for the mention of FNJN however, that contract has expired.
